<DOC>
	<DOCNO>NCT00319748</DOCNO>
	<brief_summary>The purpose study evaluate anti-tumor activity 852A use treat metastatic breast , ovarian , endometrial cervical cancer respond standard treatment .</brief_summary>
	<brief_title>Study Immune Response Modifier Treatment Breast , Ovarian , Endometrial Cervical Cancers</brief_title>
	<detailed_description>852A administer subcutaneous injection ( SC ) 2 time per week 12 week ( 24 dos ) provision dose escalation reduction base tolerability .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>Adequate performance status : Breast Karnofsky score &gt; 50 ; Ovarian , endometrial cervical Gynecologic Oncology Group ( GOG ) performance score â‰¤2 If female childbearing potential , willing use adequate contraception ( hormonal , barrier method , abstinence ) prior study entry duration study participation . Normal organ function within 14 day study entry Diagnosis one follow malignancy : Metastatic breast cancer ( BR ) Metastatic ovarian cancer ( OV ) Metastatic endometrial cancer ( EM ) Metastatic cervical cancer ( CX ) Breast Cancer Measurable metastatic disease ( &gt; 1cm ) least one site boneonly Progression failure respond least one previous chemotherapy regimen metastatic disease Progression prior therapy hormonal agent estrogen receptor progesterone receptor positive , and/or trastuzumab HER2neu positive . If patient progress hormone trastuzumab therapy , must receive one chemotherapy regimen . Ovarian Cancer Measurable metastatic disease define Response Evaluation Criteria Solid Tumors ( RECIST ) Primary tumor must diagnose histologically either epithelial ovarian cancer , fallopian tube cancer , primary peritoneal cancer ( borderline low malignant potential epithelial carcinoma ) . Subjects must fail least two previous chemotherapy regimen . Paclitaxel must component one regimens cisplatin carboplatin must component one regimen . Endometrial Cancer Measurable metastatic disease Histologically proven recurrent persistent endometrial cancer amenable curative treatment surgery and/or radiation therapy AND fail 2 previous treatment regimens Cervical Cancer Measurable metastatic disease Histologically proven recurrent persistent squamous cell carcinoma , adenosquamous carcinoma , adenocarcinoma cervix amenable curative treatment surgery and/or radiation therapy AND fail 2 previous treatment regimen . Had/have follow prior/concurrent therapy : Systemic corticosteroid ( oral injectable ) within 7 day first dose 852A ( topical inhale steroid allow ) Investigational drugs/agents within 14 day first dose 852A Immunosuppressive therapy , include cytotoxic agent within 14 day first dose 852A ( nitrosoureas within 30 day first dose ) Drugs know induce QT interval prolongation and/or induce Torsades de pointes unless best available drug require treat lifethreatening condition Radiotherapy within 3 week first dose 852A Hematopoietic cell transplantation within 4 week first dose 852A Evidence active infection within 3 day first dose 852A Active fungal infection pulmonary infiltrates ( prior treat disease stable 2 week allowable ) Cardiac ischemia , cardiac arrhythmia congestive heart failure uncontrolled medication History , clinical evidence , condition , opinion investigator , could confound result study put subject undue risk Uncontrolled intercurrent chronic illness Active autoimmune disease require immunosuppressive therapy within 30 day Active coagulation disorder control medication Pregnant lactating Concurrent malignancy ( remission , least 5 year disease free ) except localize ( insitu ) disease , basal carcinomas cutaneous squamous cell carcinoma adequately treat Any history brain metastasis active central nervous system ( CNS ) disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Breast</keyword>
	<keyword>Ovarian</keyword>
	<keyword>Endometrial</keyword>
	<keyword>Cervical</keyword>
	<keyword>Metastatic</keyword>
	<keyword>852A</keyword>
	<keyword>IRM</keyword>
	<keyword>Oncology</keyword>
	<keyword>Metastatic Cervical Cancer</keyword>
	<keyword>Metastatic Ovarian Cancer</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Metastatic Endometrial Cancer</keyword>
</DOC>